- Home
- APRE vs CVKD Comparison
APRE vs CVKD Comparison
Compare APRE & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APRE | CVKD |
|---|---|---|
| Founded | 2006 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 9.9M |
| IPO Year | 2019 | 2022 |
Fundamental Metrics
Financial Performance| Metric | APRE | CVKD |
|---|---|---|
| Price | $0.72 | $4.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.10 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 216.2K | 40.0K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.22 | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $4.21 |
| 52 Week High | $2.22 | $17.50 |
Technical Indicators
Market Signals| Indicator | APRE | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 32.93 |
| Support Level | $0.55 | N/A |
| Resistance Level | $0.98 | $14.21 |
| Average True Range (ATR) | 0.07 | 0.68 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 48.08 | 13.20 |
Price Performance
Historical ComparisonAbout APRE Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.